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Identification of Amino Acid Residues of the NR2A Subunit That
Control Glutamate Potency in Recombinant NR1/NR2A
NMDA Receptors
Lesley C. Anson,1,2 Philip E. Chen,1,2 David J. A. Wyllie,2 David Colquhoun,1,2 and Ralf Schoepfer1,2
University College London, 1Wellcome Laboratory for Molecular Pharmacology, and 2Department of Pharmacology,
London WC1E 6BT, United Kingdom
The NMDA type of ligand-gated glutamate receptor requires the
presence of both glutamate and glycine for gating. These re-
ceptors are hetero-oligomers of NR1 and NR2 subunits. Previ-
ously it was thought that the binding sites for glycine and
glutamate were formed by residues on the NR1 subunit. In-
deed, it has been shown that the effects of glycine are con-
trolled by residues on the NR1 subunit, and a “Venus flytrap”
model for the glycine binding site has been suggested by
analogy with bacterial periplasmic amino acid binding proteins.
By analysis of 10 mutant NMDA receptors, we now show that
residues on the NR2A subunit control glutamate potency in
recombinant NR1/NR2A receptors, without affecting glycine
potency. Furthermore, we provide evidence that, at least for
some mutated residues, the reduced potency of glutamate
cannot be explained by alteration of gating but has to be
caused primarily by impairing the binding of the agonist to the
resting state of the receptor. One NR2A mutant, NR2A(T671A),
had an EC50 for glutamate 1000-fold greater than wild type and
a 255-fold reduced affinity for APV, yet it had single-channel
openings very similar to those of wild type. Therefore we pro-
pose that the glutamate binding site is located on NR2 subunits
and (taking our data together with previous work) is not on the
NR1 subunit. Our data further imply that each NMDA receptor
subunit possesses a binding site for an agonist (glutamate or
glycine).
Key words: N-methyl-D-aspartate (NMDA); glutamate; recep-
tor; recombinant; subunit; ligand; binding; gating; single-chan-
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The NMDA type of glutamate receptor forms a subfamily of
ionotropic receptors with distinctive functional and biophysical
properties. NMDA receptors play an important role in synaptic
plasticity, memory and learning, brain development and excito-
toxicity (for review, see Choi, 1988; McBain and Mayer, 1994;
Collingridge and Bliss, 1995). Molecular cloning has identified a
family of genes that code for subunits of ionotropic glutamate
receptors (for review, see Nakanishi, 1992; Hollmann and Hei-
nemann, 1994). One subfamily, GluR1–4, codes for the AMPA
type of glutamate receptors; five other genes (NR1 and
NR2A–D) code for NMDA receptor subunits.
NMDA receptors are endowed with a set of properties that
distinguish them from other ionotropic glutamate receptors.
Magnesium ions block the NMDA receptor channel at the resting
potential, and current flows only when the synaptic release of
agonist coincides with depolarization, so the receptor may act as
a coincidence detector. NMDA receptor channels show a high
permeability for calcium ions, the influx of which can trigger
important cellular processes.
In the context of this paper two features are of special interest.
(1) Both glutamate and glycine have to be present for efficient
gating of the NMDA receptor channel. This requirement for a
coagonist is in contrast to all other known glutamate receptors.
(2) NMDA receptors are hetero-oligomers that are composed of
at least two types of subunit: the constant NR1 subunit, which
comes in multiple splice variants, and one or more types of an
NR2 subunit of which four (NR2A–D) variants are known. This
is in contrast to the recombinant AMPA type of glutamate
receptors, which can be either homo-oligomers or hetero-
oligomers of GluR1–4 subunits.
After the initial cloning of the NR1 subunit (Moriyoshi et al.,
1991), it was suggested that the binding sites for glutamate and
glycine are located on the NR1 subunit. Indeed, site-directed
mutagenesis of the NR1 subunit has identified amino acid resi-
dues that control glycine potency (Kuryatov et al., 1994; Wafford
et al., 1995; Hirai et al., 1996; Williams et al., 1996). In these
studies, single amino acid mutations reduced glycine potency by
up to four orders of magnitude, with only small effects on gluta-
mate potency. These studies suggest further that the glycine
binding pocket has a bi-lobar structure, similar to that found by
crystallography for a family of bacterial periplasmic amino acid
binding proteins (Oh et al., 1993, 1994), in which the ligand is
bound in a “Venus flytrap” mechanism.
Here we report the identification of amino acids, through
site-directed mutagenesis, that control glutamate potency in re-
combinant NR1/NR2A receptors. These residues were found on
the NR2A subunit, at positions homologous to those on the NR1
subunit that control glycine potency. Similar conclusions were
published recently by Laube et al. (1997). Furthermore, we now
provide evidence that at least some of these residues shape the
glutamate binding site. Thus, the overall folding of the area of
NR2 subunits that binds glutamate is likely to be structurally
similar to the area of the NR1 subunit that binds glycine.
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MATERIALS AND METHODS
Expression plasmid constructs. The wild-type expression plasmids for the
rat NR1 (1a splice form) and NR2A NMDA receptor subunits were as
in Kuner and Schoepfer (1996). Mutations were introduced into the
NR2A sequence by a PCR-based strategy. To facilitate cloning and
identification of mutants, some NR2A mutants carried additional silent
nucleotide substitutions. PCR-generated DNA segments and cloning
sites were confirmed by DNA sequencing.
Heterologous expression of NMDA receptors. cRNA was synthesized as
runoff transcripts from linearized plasmid DNA using the Promega
(Madison WI) RiboMax RNA synthesis kit. Reactions were supple-
mented with 0.75 mM capping nucleotide m 7G(59)ppp(59)G (Pharmacia,
Uppsala, Sweden) in the presence of 1.6 mM GTP. cRNA amounts and
integrity were estimated by intensity of fluorescence in ethidium
bromide-stained agarose gels, and concentration was determined also by
OD260. NR1 and NR2A cRNAs were mixed at a nominal ratio of 1:1 and
diluted with water to ;5 ng/ml of each, before injection. Xenopus laevis
oocytes (stage V) were isolated manually after collagenase treatment
(Sigma type V, 30 mg/ml, at room temperature for 1 hr). Oocytes were
then defolliculated and injected (Drummond Injector) with 23 nl of
cRNA mixture. For expression the oocytes were incubated at 19°C for
2–3 d in modified Barth’s solution (in mM): NaCl 88, KCl 1, NaHCO3
2.4, Ca(NO3 )2 0.33, MgSO4 0.82, CaCl2 0.44, Tris-Cl 15, adjusted to pH
7.4 with NaOH, supplemented with 50 IU/ml penicillin (BRL, Bethesda,
MD), 50 mg/ml streptomycin (BRL), and 30 mM D(2)-2-amino-5-
phosphonopentanoic acid (APV) (Tocris), followed by storage at 4°C
until they were used for electrophysiological measurements.
Whole-oocyte recording. Responses to glutamate were measured with a
two-electrode voltage-clamp amplifier (TEC05, NPI electronics, Tamm,
Germany) at 260 mV using 0.5–2.0 MV electrodes filled with 3 M KCl.
Oocytes were perfused with nominally Ca 21-free, low-Ba 21 NFR solu-
tion (in mM): NaCl 115, KCl 2.5, HEPES 10, adjusted to pH 7.2 with HCl
and supplemented with 0.18 mM BaCl2 unless noted otherwise.
Glutamate stock solutions (1 M in H2O) were neutralized with
N-methyl-D-glucamine. APV was stored as 100 mM stock neutralized
with NaOH. All stock solutions were stored at 220°C. For measurements
NFR was further supplemented with 30 mM glycine (for glutamate
dose–response measurements), or with 30 mM to 1 mM glutamate, de-
pending on the glutamate potency of each receptor (for glycine dose–
response measurements).
Application of solutions was computer-controlled by the program
EggWorks. Applications of agonist were kept as short as possible, con-
sistent with reaching a plateau or peak response. Data were recorded
simultaneously on a chart recorder and on a computer hard disk. For
digital recording, data were filtered at 100 Hz digitized at 300 Hz and
reduced to a final sampling rate of 10 Hz (oversampling with equal
weight averaging of 30 samples) before storage.
Data analysis for dose–response curves. Dose–response curves were
fitted individually for each oocyte with the Hill equation:
I 5 Imax /~1 1 ~EC50 / @A#!nH!
where nH is the Hill coefficient, Imax is the maximum current, [A] is the
concentration of agonist, and EC50 is the concentration of agonist that
produces a half-maximum response. Each data point was then normal-
ized to the fitted maximum of the dose–response curve.
The normalized values were then pooled and averaged for each mutant
and fitted again with the Hill equation.
Schild analysis. APV antagonism was examined by the Schild method
(Arunlakshana and Schild, 1959). Recording conditions were as described
above, with the exception that the perfusion solution contained 1.8 mM
BaCl2. Oocytes were perfused for 60 sec with APV-supplemented perfu-
sion solution before application of glutamate in the presence of APV. Dose
ratios from individual oocytes were determined at low agonist concentra-
tions as follows. The currents induced by two concentrations (,, EC50 ) of
agonist were determined in the absence of APV. Responses in the presence
of a series of APV concentrations were then obtained with glutamate
concentrations increased to produce similar responses.
The resulting set of two-point dose–response curves was fitted with the
low-concentration limit of the Hill equation, i.e., with the power function
y 5 (x/x0 )
n. This gives straight lines on log–log coordinates, and the lines
were constrained to be parallel by fitting the same n for all curves. The
dose ratios (r, defined as the ratio of the glutamate concentrations needed
to produce the same response in the presence and absence of APV) were
obtained for each APV concentration from this fit. The mean dose ratios
for each concentration of APV were used to construct a Schild plot, of
log(r 21) versus log [B] where [B] is the antagonist concentration. This
was initially fitted with a straight line, not in logarithmic form, but by
fitting the (r 21) and [B] values with a power function as above. In this
form n is the slope of the Schild plot, which is predicted by the Schild
equation to be unity for a competitive antagonist at equilibrium. If n was
sufficiently close to 1, then the results were to be taken to be consistent
with the Schild equation, so the data were refitted with the slope fixed at
1, i.e., they were refitted with the Schild equation (r 2 1) 5 [B]/KB in
which the only free parameter is the equilibrium constant for antagonist
binding, KB.
Single-channel recordings. Oocytes with agonist-induced Imax . 0.5 mA
at 260 mV were selected for single-channel recording. Before making
patch-clamp recordings, the vitelline membrane of each oocyte was
removed in a hypertonic solution containing (in mM): sodium methylsul-
fate 200, KCl 20, MgCl2 1, HEPES 10, pH 7.4, with KOH. Recordings of
channel activity in outside-out patches were made in an external solution
containing (in mM): NaCl 125, KCl 3, NaH2PO4 1.25, HEPES 20, CaCl2
0.85, pH 7.4, with NaOH supplemented with 20 mM glycine. “Low”
glutamate concentrations were used. Because of the low glutamate po-
tency on the T671A mutant, a “low concentration” means 30–200 mM,
1000-fold larger than used for the wild type. Patch pipettes, made from
thick-walled borosilicate glass (Clark Electromedical Instruments, Pan-
gbourne, UK), contained (in mM): potassium gluconate 141, NaCl 2.5,
HEPES 10, EGTA 11, pH 7.4, with KOH. After fire-polishing of their
tips, pipettes had resistance of 10–20 MV. Single-channel currents were
recorded with an Axopatch-1D amplifier (Axon Instruments, Foster City,
CA) and stored on digital audio tape (Biological DTR 1200/1205). For
subsequent analysis, data were filtered at 2 kHz (23 dB) before digiti-
zation at 20 kHz. Channel durations and amplitudes were fitted with the
SCAN program (Colquhoun and Sigworth, 1995) and subjected to a 70
msec imposed resolution. We define an open period as a period during
which the channel appeared to be continuously open, regardless of
transitions between different open levels. Chord conductance values
assume a reversal potential of 0 mV, which is close to the observed
reversal potential between 0 and 10 mV. Observed channel activity was
blocked by the glycine site antagonist 7-chlorokynurenic acid (25–50 mM).
Concentration jump experiments. Fast concentration jumps were
achieved by the rapid switching, across the tip of a patch pipette, of two
solutions flowing from either side of a piece of theta glass. The control
solution was supplemented with 20 mM glycine, and the test solution
contained 10 mM glutamate (1 20 mM glycine). Outside-out patches, held
at 2100 mV, were exposed to glutamate for 100 msec, and jumps were
made every 10 sec. Measurement of liquid junction potentials at the end
of experiments indicated that the exchange of control and test solutions
occurred within 300 msec.
RESULTS
NR2A mutations
Ten mutants containing single amino acid substitutions of the
NR2A subunit were generated by site-directed mutagenesis, at
positions that were chosen either because they control glycine
potency on NR1 subunits, or because they control amino acid
binding in bacterial binding proteins. Alignment of NR2 sequences
with bacterial amino acid binding proteins (Fig. 1A) reveals limited
linear sequence identity in segments N terminal of M1 and C
terminal of M3, in extracellular domains referred to as S1 and S2,
respectively (Stern-Bach et al., 1994). The corresponding segments
on NR1 harbor residues that control glycine potency (Kuryatov et
al., 1994). Mutants were generated according to the following rule:
uncharged amino acids were mutated into alanine, positive charges
were substituted by negative charges, and in addition aromatic
residues were replaced by another aromatic residue.
Recombinant coexpression of NR1 cRNA with any of the 10
mutant NR2A cRNAs resulted in robust inward currents after
the application of glutamate in the presence of glycine (Fig. 1B).
Injection of similar amounts of cRNA resulted in maximal
agonist-induced currents of comparable magnitude; in particular,
Imax for the mutants was generally not lower than Imax for the wild
type (the values are given in the legend of Fig. 2).
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Reduced potency of glutamate
Dose–response curves were recorded (Fig. 1B) in conditions (180
mM Ba21) designed to minimize the artifacts caused by agonist-
induced influx of divalent cations (Leonard and Kelso, 1990;
Williams, 1993). With the exception of NR2A(G664A), all of the
mutations we tested shifted the dose–response curves for gluta-
mate to the right (Fig. 2A). For all mutations except S670A (and
G664A), the potency of glutamate was reduced by more than
fivefold. Three mutations (H466A, G669A, and T671A) de-
creased the potency of glutamate by more than two orders of
magnitude (Table 1). The fitted dose–response curves (Fig. 2A)
show that the Hill coefficients for most of the 10 mutant receptors
Figure 1. Single amino acid substitutions in the NR2A subunit generated functional NR1/NR2A receptors. A, Amino acid sequence alignment of rat NR1
(Moriyoshi et al., 1991) and NR2 subunits (Monyer et al., 1992; Ishii et al., 1993) with the bacterial periplasmic binding proteins LAOBP (Oh et al., 1993)
and HISJ (Oh et al., 1994). Residues that reduced glycine potency when mutated in NR1 are marked by an arrow above the sequence alignment. NR2A
residues that were mutated in this study are marked below the sequence alignments by an arrow if the mutation reduced potency by more than a factor of
2; otherwise they are indicated by a minus sign. Numbers indicate the first residue of the alignment; numbering is for mature proteins without signal peptides.
B, Glutamate-activated currents recorded in the two-electrode voltage-clamp configuration from an oocyte expressing wild-type receptors (lef t) and an
oocyte expressing T671A mutant receptors (right). Increasing concentrations of glutamate were applied in the presence of 30 mM glycine.
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are not much different from the value found for wild-type NR1/
NR2A receptors. The slopes for H466F and V666A are probably
lower, and for K465E may be higher, than for the wild type, but
the three mutations with the largest increase in EC50 show little or
no change of the Hill slope.
In contrast to the considerable effect of the mutations on
glutamate potency, the potency of the coagonist glycine
was barely affected; the EC50 values for all 10 mutants lay
within a factor of 1.7 of that of the wild type, as shown in
Figure 2 B.
Figure 2. Mean normalized dose–response relationships for glutamate
and glycine. A, Glutamate-activated currents were evoked in the presence
of 30 mM glycine. Mean dose–response curves for wild-type ( filled squares,
mean of fitted Imax 5 0.41 mA), N463A (open diamonds, 1.3 mA), K465E
( filled pentagons, 1.6 mA), H466A ( filled diamonds, 1.4 mA), H466F ( filled
circles, 1.8 mA), G664A (open triangles, 1.1 mA), T665A (open squares, 0.42
mA), V666A ( plus signs, 1.7 mA), G669A (open circles, 3.7 mA), S670A
(open hexagons, 0.38 mA), and T671A ( filled hexagons, 2.0 mA) receptors
were fitted with the Hill equation as described in Materials and Methods.
Error bars have been omitted for clarity. The points represent the means
of two to eight observations. B, Glycine-activated currents were evoked in
the presence of a saturating concentration of glutamate (30 mM to 10 mM
depending on glutamate potency for each receptor). Dose–response curves
were constructed as in A. Symbols represent the same as in A.
Table 1. EC50 and Hill values for glutamate and glycine
Glutamate Glycine
EC50 (mM) nH n EC50 (mM) nH n
NR1/NR2A 2.89 6 0.12 1.49 6 0.09 8 2.62 6 0.19 1.54 6 0.15 6
NR1/NR2A(N463A) 17.9 6 1.4 1.70 6 0.18 3 2.50 6 0.16 1.78 6 0.18 4
NR1/NR2A(K465E) 29.3 6 1.4 1.91 6 0.18 4 3.11 6 0.27 1.64 6 0.20 3
NR1/NR2A(H466A) 624 6 32 1.55 6 0.09 6 3.67 6 0.22 1.54 6 0.12 4
NR1/NR2A(H466F) 38.4 6 4.6 1.09 6 0.10 4 2.10 6 0.22 1.69 6 0.24 3
NR1/NR2A(G664A) 2.08 6 0.25 1.46 6 0.21 3 1.69 6 0.21 1.44 6 0.21 3
NR1/NR2A(T665A) 19.0 6 2.0 1.18 6 0.11 3 3.86 6 0.39 1.39 6 0.15 5
NR1/NR2A(V666A) 33.4 6 1.6 1.12 6 0.05 5 4.53 6 0.31 1.35 6 0.10 4
NR1/NR2A(G669A) 927 6 46 1.38 6 0.07 4 3.58 6 0.23 1.39 6 0.10 4
NR1/NR2A(S670A) 4.97 6 0.30 1.35 6 0.09 5 3.49 6 0.39 1.57 6 0.24 3
NR1/NR2A(T671A) 2967 6 279 1.30 6 0.09 5 2.94 6 0.23 1.29 6 0.10 4
584 J. Neurosci., January 15, 1998, 18(2):581–589 Anson et al. • Glutamate Binding Site of NMDA Receptors
Reduced affinity for APV
To examine the underlying mechanism that is responsible for the
decreased potency of glutamate (see Discussion), we analyzed the
NR1/NR2A(T671A) mutant in greater detail. Schild’s method
(Arunlakshana and Schild, 1959) was used to determine the equi-
librium constant, KB, for the competitive antagonist APV (Fig. 3).
The slope of the Schild plot was 1.06 6 0.04 for the wild type and
0.94 6 0.16 for T671A. These values are close to (and do not differ
significantly from) 1.0, so there is no evidence against the view that
APV is a competitive antagonist on both receptors. Therefore the
plots were refitted with the Schild equation (slope fixed at 1), as
described in Materials and Methods, and these fits are shown in
Figure 3C. For the wild type we found that KB 5 1.26 6 0.07 mM,
which is similar to the value of 1.35 mM reported by Verdoorn et al.
(1989) for rat brain mRNA expressed in oocytes. For the T671A
mutant, however, we found a much reduced affinity for APV, with
KB 5 321 6 30 mM. This 255-fold reduction in affinity is compa-
rable with the 1000-fold reduction of potency for glutamate.
Single-channel conductance
The single-channel currents evoked by glutamate in NR1/
NR2A(T671A) were remarkably similar to those evoked in the
wild type (Fig. 4). The mean chord conductances of their main
level and sublevel were estimated as 51.1 6 1.1 pS and 38.6 6 0.9
pS (n 5 5), compared with values of 50.1 6 1.4 pS and 38.3 6 1.3
pS reported for wild-type NR1/NR2A by Stern et al. (1992). The
relative areas for these two components, 85% and 15%, were also
similar to those for wild type (80% and 20%). In addition, the
frequencies of direct transitions from shut to main level, from
shut to sublevel, and from main to sublevel of T671A channels
(Table 2) were similar to those reported for the wild type by Stern
et al. (1992). Like the wild-type NR1/NR2A, they showed no sign
at all of the sort of temporal asymmetry shown by NR1/NR2D
receptors (Wyllie et al., 1996).
Single-channel kinetics
In contrast to the close similarity of the conductances, there were
kinetic differences between T671A and the wild type. For exam-
ple, both mutant and wild-type open period distributions con-
tained three exponential components (Fig. 5). The mean time
constants for each component were 66.2 6 17.0 msec, 1.10 6 0.34
msec, and 6.91 6 2.45 msec for T671A channels (n 5 5), and
47.6 6 9.3 msec, 0.823 6 0.375 msec, and 3.08 6 0.57 msec for
wild-type channels (n 5 5) (P. Be´he´ and D. Wyllie, personal
communication). The overall mean apparent length of the open
periods was 4.33 6 0.71 msec for T671A compared with 1.69 6
0.16 msec for the wild type (also see Fig. 4). These values are
clearly different ( p 5 0.0045 by two-tailed randomization test).
For this comparison, both wild-type and mutant data were
analyzed with the same resolution (70 msec for both open and shut
times). Such a resolution would mean that a substantial number of
brief shuttings were missed; however, it is not possible to do a
satisfactory correction for missed events without knowledge of a
realistic kinetic mechanism (Colquhoun and Hawkes, 1995).Figure 3. Schild analysis of the competitive antagonism of the glutamate
binding site by APV. A, Partial, low-concentration, glutamate dose–
response curves for one oocyte expressing wild-type receptors in the
absence (open squares) and presence of 3 mM ( filled diamonds), 10 mM
(open pentagons), 30 mM ( filled hexagons), and 100 mM (open circles) APV.
Dashed lines represent free fits of the power function (see Materials and
Methods) to the data, and solid lines show fits of the same function but
with slopes constrained to be the same for all curves. Fitted lines have
been extrapolated for display purposes. B, Partial, low-concentration,
glutamate dose–response curves for one oocyte expressing T671A mutant
receptors in the absence ( filled pentagons) and presence of
4
300 mM (open diamonds) and 1 mM ( filled triangles) APV. Data were fitted
as in A. C, Schild plot for antagonism of wild-type ( filled circles) and
T671A ( filled squares) receptors by APV using dose ratios estimated from
results such as those in A and B. The points represent the means of five
dose ratios. The dashed lines are free fits with slopes that are not exactly
1; the solid lines are fits of the Schild equation (both have slope 5 1).
Fitted lines have been extrapolated for display purposes.
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Kinetic differences between mutant and wild-type receptors
were also observed in concentration jump experiments. Prelimi-
nary data, shown in Figure 6, indicate that deactivation of T671A
receptors, after a 100 msec jump of 10 mM glutamate, occurs with
a time constant of 18.2 6 3.0 msec (n 5 4). This is approximately
one order of magnitude faster than that found for the deactivation
of wild-type NR1/NR2A channels after “long” pulses of gluta-
mate (Monyer et al., 1992; Medina et al., 1995) (D. Wyllie and P.
Be´he´, personal communication).
DISCUSSION
Glutamate effects are mediated through NR2 subunits
We have shown that mutagenesis of NR2A residues reduced the
potency of glutamate by up to 1000-fold, with very little effect on
Figure 4. Wild-type and T671A single-channel amplitudes. A, Single-channel currents recorded in an outside-out patch from an oocyte expressing
T671A mutant receptors in the presence of 60 mM glutamate and 20 mM glycine. At 2100 mV a main level (;5 pA) and a sublevel (;4 pA) are clearly
visible. B, Wild-type single-channel currents adapted from Be´he´ et al. (1995). Transitions between the main level (;5 pA) and sublevel (;4 pA) are
evident. C, Amplitude histogram of 791 events of duration greater than 2.5 filter rise times, for the patch illustrated in A. The distribution was fitted with
two Gaussian components with means of 5.18 and 4.15 pA D, Amplitude histogram for the same patch as in B reanalyzed from Be´he´ et al. (1995). The
distribution of 1048 events greater than 2.5 rise times was fitted with two Gaussian components with means of 5.52 and 4.35 pA.
Table 2. Transitions between conductance levels for NR1/NR2A(T671A)
channels
Transition type n (N 5 10897)a %
Shut-sublevel 400 3.67
Sublevel-shut 366 3.36
Shut-main level 4210 38.63
Main level-shut 4241 38.92
Sublevel-main level 860 7.89
Main level-shut 820 7.53
Experiments were performed in the presence of 20 mM glycine and between 60 and
200 mM glutamate.
aN refers to the total number of transitions, longer than 2.5 tr, analyzed from five
recordings.
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the potency of glycine. Our evidence strongly suggests (see be-
low) that the binding site for glutamate on NMDA NR1/NR2A
receptors is formed by NR2A subunits. The residues we found to
be important in NR2A are fully conserved within the NR2 family
(Fig. 1A), which suggests that in all types of NR1/NR2 NMDA
receptors glutamate effects are mediated by the NR2 subunit.
Comparison of our data with the results of Kuryatov et al. (1994)
and Wafford et al. (1995) on glycine potency of NR1 mutations
suggests that the glutamate effects mediated through the NR2
subunits, and glycine effects mediated through the NR1 subunit,
are each based on the same structural design.
While the experiments described here were in progress, Laube
et al. (1997) reported that mutation of NR2B residues reduced
glutamate potency on NR1/NR2B receptors. Three of their
mutations were equivalent to ours; for two of them we both found
a comparable (approximately 10-fold) reduction in potency of
glutamate (H466F, V666A), whereas for one (K465E, equivalent
to NR2B K459E) we found a considerably smaller effect. For
NR2A S670, we analyzed the effect of the mutation to alanine,
S670A, and found only a minimal effect; the same serine to
alanine mutation at the equivalent position on the NR1 subunit
also has little effect on glycine potency (Kuryatov et al., 1994). In
contrast, Laube et al. (1997) report a 180-fold reduction of glu-
tamate potency for a mutation into glycine at the homologous
position (S664G). The mutations that gave the three largest
increases in glutamate EC50 in Laube et al. (1997) (236-, 180-, and
118-fold) were all at different positions from those that gave the
largest shifts here (1027-, 321-, and 216-fold). Furthermore their
mutant with the largest shift actually showed a decreased IC50 for
APV, although that with the 180-fold shift showed a 40-fold
increase in IC50. Our most-shifted mutant, T671A, showed a
255-fold increase in the equilibrium binding constant of APV.
Laube et al. (1997) proposed an appealing three-dimensional
arrangement for the structure of the glutamate binding site, and
it will be interesting to see how this proposal can accommodate
the rather different residues that seem, from the mutants tested
here, to be important for glutamate binding.
Evidence that reduced potency is caused by impaired
binding of glutamate
The basis for the inference that the mutated residues form part of
the glutamate binding site requires clarification. A reduction of
potency is not necessarily caused by a change in the binding site
but can also be caused by a change of gating. In other words, the
glutamate binding site might not be affected at all; furthermore,
a binding assay for glutamate would not resolve this ambiguity
(see Colquhoun and Farrant, 1993).
To infer that the mutated residues form part of the binding site
it is necessary to show that the mutation has altered the micro-
scopic equilibrium constant for the initial binding step: the bind-
ing of glutamate to the resting state of the receptor. If this were
the only change we could say that it was very likely that these
domains form part of the glutamate binding site (we do not
distinguish in this paper between residues that interact directly
with the ligand and residues that shape the binding site without
direct interaction with the ligand).
One way to examine this problem is to use a competitive
antagonist rather than an agonist. This removes most of the
complications in interpretation of the effect of a mutation, be-
cause a competitive antagonist, unlike an agonist, is not expected
to cause a change of the receptor conformation to higher-affinity
active states (i.e., gating). Thus any change in their binding is
likely to result directly from a change in the binding site. The
equilibrium constant for antagonist binding, KB, cannot be deter-
mined from IC50 measurements, so Schild’s method was used. It
is possible that binding of the agonist might be altered in a mutant
receptor without alteration of binding of a competitive antago-
nist, because the binding sites for the two compounds, although
presumably overlapping, are not identical. However, we found
Figure 5. Open period distribution for T671A mutant and wild-type
channels. A, Distribution of the length of 1947 apparent open periods
evoked by 200 mM glutamate and 20 mM glycine in a patch containing
T671A mutant channels. The distribution was fitted with a mixture of three
exponential densities with parameters as shown. B, Distribution of 949
apparent open periods evoked by 30 nM glutamate (120 mM glycine) in a
patch excised from an oocyte expressing wild-type NR1/NR2A receptors.
The distribution was fitted with a mixture of three exponential components.
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that the T671A mutation increased the equilibrium binding con-
stant 255-fold for APV compared with wild type. Therefore in
this mutant, APV binding is impaired greatly, which implies that
its binding site, and therefore probably that for glutamate, has
been altered.
The equilibrium concentration–response curves also suggest a
primary effect of the mutation on the binding site for glutamate.
The main finding is that mutations in the NR2 subunit can produce
an enormous reduction in the potency of glutamate (EC50), with
little change in the Hill slope, and very little change in the potency
of glycine (Table 1). Of the three most effective mutations, one
precedes M1 (S1 domain) and the others follow M3 (S2 domain),
which suggests that both regions contribute to the binding site.
A reduction in the open-shut equilibrium constant could pro-
duce this result without any detectable change in maximum
response, provided that its reduced value is still such that most
channels are open at equilibrium. How can we exclude this
possibility? The first reason is that for many cooperative mecha-
nisms we expect the shift of the EC50 to be proportional to the
binding constants but roughly proportional (in the case of two
bindings being required) to the square root of the gating constant
(as long as this equilibrium is well over toward the open state). In
this case the 1000-fold increase in EC50 seen with T671A would
require a roughly millionfold reduction in the gating constant. If
this were to occur without a drastic reduction of the maximum
response, the gating constant for the wild-type channel would
have to be enormously high. This does not appear to be the case,
because glutamate actually behaves like a partial agonist on
NMDA receptors with a maximum Popen of ;0.3 (Gibb and
Colquhoun, 1992; Dzubay and Jahr, 1996). Therefore, such a
reduction in the gating constant would cause an enormous reduc-
tion in the maximum response. In common with almost every
mutation study, we have no good evidence as to whether the
maximum response is changed, because of uncertainties about
the relative efficiency of expression of wild-type and mutant
RNAs; however, there was no systematic difference between the
maxima observed (Fig. 2 legend), so it is clear that changes by a
factor of one million have not occurred.
Furthermore, most kinetic mechanisms predict that the Hill
slope would be reduced substantially if there were such a large
effect on the gating constant as would be required to account for
our observations; we observed no such reduced Hill slope.
Interpretation of kinetic data of the T671A mutant
In principle, effects on channel gating can be measured from
kinetic analysis of single-channel recordings (Colquhoun and Sak-
mann, 1985). We show that transition frequencies between the
conductance levels of T671A (as well as the levels themselves) are
similar to those of the wild type. Therefore, at least this aspect of
gating is not altered in the mutant with the largest reduction in
potency.
The observation that the mean apparent open period is longer
for the T671A mutant could mean that the channels stay open
rather longer, which would imply some effect on the shutting rate
of the channel, i.e., on the gating process. Such a change, however,
is in the wrong direction to explain reduced glutamate potency.
In any case it is quite conceivable that there is no real increase in
the length of individual openings; the apparent increase could
well result from more rapid dissociation of the agonist, which
would be expected to reduce the duration and frequency of brief
shuttings such that fewer of them are detected and openings
appear, incorrectly, to be longer.
Figure 6. Fast concentration jumps on the T671A mutant receptor. A,
Two individual responses obtained from an outside-out patch after a 100
msec pulse of 10 mM glutamate (in the presence of 20 mM glycine).
Single-channel currents can be seen clearly in these example traces. The
timing and duration of the glutamate application are indicated above each
pulse. B, The average of 25 such jumps. The deactivation of this ensemble
current is rapid and can be reasonably well described by a single expo-
nential with a time constant of 16 msec, shown as a white line.
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Figure 6 shows that the decay of the response, after rapid
removal of glutamate, is roughly 10-fold faster for T671A than for
wild-type receptors. The decay rate of the current is a reflection of
the length of the underlying channel activation, or burst
(Colquhoun et al., 1997). We have found that the individual open-
ings, if anything, are longer in the mutant receptor, so the fast
decay cannot be explained by shorter open times. The length of an
activation will depend on the number of times that the channel
reopens while agonist is still bound. The more rapid decay is
therefore likely to result from there being fewer reopenings during
an activation for the mutant channel compared with the wild type.
This could result from either (1) an increased rate of dissociation
of glutamate or (2) a reduced opening rate constant for the mutant
channel. If we are right in assuming that wild-type and mutant
receptors express with comparable efficiency, then, as discussed
above, it is unlikely that the opening rate constant is greatly
reduced in the mutant, so this is also unlikely to be the main reason
for the faster decay (although a contribution from this source
cannot be ruled out). Thus the main reason is likely to be that
glutamate dissociates more rapidly, thereby reducing the probabil-
ity that the channel will reopen. An increase in dissociation rate is
consistent with a reduced affinity for glutamate.
Implications
In the absence of any completely satisfactory kinetic mechanism
for the NMDA receptor, it is not possible to infer from the
results, in a rigorous manner, numerical values for the micro-
scopic equilibrium constant for the initial binding step or for the
gating constants. As discussed above, it is most likely that the
primary effect, at least for the three most effective mutations, is
on glutamate binding.
The model of a conserved structural design of agonist binding
sites of the extended ionotropic glutamate receptor family is
further supported by other studies. Paas et al. (1996) investigated
ligand binding to chick cerebellar kainate binding protein, and
Kuusinen et al. (1995) found ligand binding by a recombinant
fusion protein consisting only of fused S1 and S2 domains of an
AMPA receptor.
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